""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

psychiatry1 Psych residents psychiatry3

department of Psychiatry and Behavioral Science

Research Programs

 

The Department of Psychiatry is involved in collaborative, multidisciplinary research efforts throughout Temple University School of Medicine, the University, and with members of our Adjunct Faculty. Some of our projects and collaborations are discussed below.

 

For more information about research efforts in the Department of Psychiatry, particularly for interested residency candidates, or to discuss a patient related clinical trial please contact: Mary F. Morrison, MD, MS, Vice Chair for Research, Department of Psychiatry, Professor of Psychiatry, Internal Medicine and Center for Substance Abuse Research at: mary.morrison@tuhs.temple.edu

Psychiatry-Treatment Research Institute Collaboration at Temple University Hospital


This study will adapt evidence-based interventions into a specialized community disease management program for patients with substance use disorders who are ambivalent about addiction treatment or face significant barriers to engaging in treatment. The study will evaluate whether this approach can improve outcomes for hospitalized patients at Temple University Hospital compared with an existing disease management program after hospital discharge. Under the direction of Adam Brooks, PhD, Senior Research Scientist at Treatment Research Institute, this study will address the need for hospital systems to provide dedicated attention to patients with substance use disorders. Mary F. Morrison, MD, MS, Vice Chair for Research, Department of Psychiatry, Professor in the Department of Psychiatry and Steven R. Carson, RN, BSN, MHA, Vice President for Clinical Integration, Center for Population Health, Temple University Health System will provide leadership for the intervention at Temple University Hospital. A community advisory board will assist with the design and implementation of this project. This project was selected for PCORI funding not only for its scientific merit and commitment to engaging patients and other stakeholders, but also for its potential to fill an important gap in our health knowledge and is funded by PCORI.

 

About Treatment Research Institute
Treatment Research Institute has been a leader in the substance use research filed with a belief that science can only be truly impactful when it is used to improve policies, programs, and practices.

 

About PCORI
The Patient-Centered Outcomes Research Institute (PCORI) is an independent, non-profit organization authorized by Congress in 2010. Its mission is to fund research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed health care decisions.

 

Return to top

 

 

Center for the Development of Novel Medications for Cocaine Dependence

 

Cocaine addiction is a devastating disorder and there are no effective medications for treatment. The center will determine the safety and efficacy signals of novel medications for cocaine dependence. Dr. Kyle Kampman, Professor of Psychiatry at the University of Pennsylvania is the Principal Investigator of the Cocaine Center and Dr. Mary F. Morrison, Vice Chairperson for Research and Professor in the Department of Psychiatry is the Temple University Lead Investigator. Dr. Ingre Walters, Assistant Professor of Psychiatry and Dr. Carol Homko, Associate Professor of Medicine are also involved in the research at Temple. The Center is funded by the National Institute of Drug Abuse.


Return to top

 

 

Center for Substance Abuse Research


This NIH-funded research center serves to facilitate multidisciplinary research on drugs of abuse and the consequences of their use, whether abused or therapeutic. This mission encompasses understanding the effects of the drugs on various systems in the body, as well as the study of the receptors to which the drugs bind, the signal transduction pathways they evoke, alterations that they induce in gene expression, neuronal pathways that they stimulate, and behaviors that they induce. Ellen Unterwald, MD, Professor of Pharmacology, is the Director of the Center.


Research on substance abuse is particularly important to the Department because a significant proportion of the patients treated by us have problems with drug abuse. Substance abuse is an important contributing factor to other psychiatric disorders. The course of psychiatric illness can be affected by co-existing substance abuse, which can also impede effective treatment. A better understanding of the social, psychological and biological factors influencing vulnerability to and treatment of substance abuse will relieve disease burden and improve outcomes for many of our patients.

 

Link to CSAR home page

 

Return to top

 


Clinical Trials - Treatment Resistant Depression

 

Rapid-KOR study is a Phase II double-blind placebo-controlled, trial of Cerc-501 a kappa selective opioid receptor antagonist, as augmentation of antidepressant therapy in Treatment Resistant Depression. The study drug is taken once per day for 6 days along with current antidepressant medication. Participation involves 10 clinic visits over a 1 month period. This study is funded by the National Institute of Mental Health. The Principal Investigator at Temple is Mary F. Morrison, MD, MS.

 

You may be eligible to participate if you:

  • are 18 to 65 years old
  • are in overall good physical health
  • are not currently experiencing stomach ulcers or gastrointestinal disease
  • have been diagnosed with Major Depressive Disorder
  • currently experiencing depression symptoms such as low mood, lack of energy, appetite and sleep disturbance and feelings of worthlessness and guilt
  • currently taken an antidepressant medication that is not working to relieve your symptoms

Contact Jennifer Henry, MA to learn more about the study and to see if you are eligible at 215-707-8204 or Jennifer.Henry@tuhs.temple.edu.

 

Return to top